Dual effect of the novel peptide antagonist K-14585 on proteinase-activated receptor-2-mediated signaling

Fui Goon Goh, Pei Yuen Ng, Mary Nilsson, Toru Kanke, Robin Plevin

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Background and purpose: Here we have examined the effects of the novel peptide antagonist N-[1-(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H- indol-5-yl]aminocarbonyl}-glycinyl-L-lysinyl-L-phenylalanyl-N-benzhydrylamide (K-14585) on proteinase-activated receptor (PAR) 2-mediated intracellular signalling events. Experimental approach: Using NCTC2544 cells expressing PAR 2, we assessed the effects of K-14585 on PAR 2-mediated [ 3H] inositol phosphate accumulation, MAP kinase activation, p65 NFκB phosphorylation and DNA binding and IL-8 production. Key results: Pretreatment with K-14585 (5 μM) inhibited [ 3H] inositol phosphate levels stimulated by PAR 2- activating peptide Ser-Leu-Ile-Gly-Lys-Val (SLIGKV-OH) in PAR 2-expressing NCTC2544 cells. K-14585 pretreatment did not influence PAR 2-mediated extracellular regulated kinase activation but inhibited p38 MAP kinase phosphorylation. At a higher concentration (30 μM), K-14585 alone stimulated p38 MAP kinase activation. These effects were replicated in EAhy926 cells, endogenously expressing PAR 2, but not in parental or PAR 4-expressing NCTC2544 cells, suggesting these effects were PAR 2-dependent. SLIGKV-mediated stimulation of p38 MAP kinase phosphorylation was substantially reduced by the G q/11 inhibitor YM-254890, without affecting K-14585-mediated phosphorylation. Pretreatment with K-14585 inhibited PAR 2-mediated p65 NFκB phosphorylation and NFκB-DNA binding. K-14585 (30 μM) alone stimulated comparable NFκB reporter activity to SLIGKV-OH. K-14585 inhibited SLIGKV-stimulated IL-8 production, but given alone increased IL-8. While SLIGKV-induced IL-8 formation was reduced by both SB203580 and YM-254890, the response to K-14585 was sensitive to SB203580 but not YM-254890. Conclusions and implications: These data reveal that K-14585 has a duality of action functioning both as an antagonist and agonist due to either partial agonist actions or possible agonist-directed signalling. The data also suggest two modes of p38 MAP kinase activation emanating from PAR 2, one G q/11-dependent and the other G q/11-independent.

Original languageEnglish
Pages (from-to)1695-1704
Number of pages10
JournalBritish Journal of Pharmacology
Volume158
Issue number7
DOIs
Publication statusPublished - Dec 2009
Externally publishedYes

Fingerprint

PAR-2 Receptor
seryl-leucyl-isoleucyl--glycyl-lysyl-valine
Peptides
p38 Mitogen-Activated Protein Kinases
Interleukin-8
Phosphorylation
Inositol Phosphates
K-14585
Proteinase-Activated Receptors
eIF-2 Kinase
DNA

Keywords

  • G signalling
  • Inositol phosphate
  • K-14585 peptide antagonist
  • P38 MAP kinase
  • PAR

ASJC Scopus subject areas

  • Pharmacology

Cite this

Dual effect of the novel peptide antagonist K-14585 on proteinase-activated receptor-2-mediated signaling. / Goh, Fui Goon; Ng, Pei Yuen; Nilsson, Mary; Kanke, Toru; Plevin, Robin.

In: British Journal of Pharmacology, Vol. 158, No. 7, 12.2009, p. 1695-1704.

Research output: Contribution to journalArticle

Goh, Fui Goon ; Ng, Pei Yuen ; Nilsson, Mary ; Kanke, Toru ; Plevin, Robin. / Dual effect of the novel peptide antagonist K-14585 on proteinase-activated receptor-2-mediated signaling. In: British Journal of Pharmacology. 2009 ; Vol. 158, No. 7. pp. 1695-1704.
@article{d2fe7a69491a4ebd9fb9b7f592dcd2af,
title = "Dual effect of the novel peptide antagonist K-14585 on proteinase-activated receptor-2-mediated signaling",
abstract = "Background and purpose: Here we have examined the effects of the novel peptide antagonist N-[1-(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H- indol-5-yl]aminocarbonyl}-glycinyl-L-lysinyl-L-phenylalanyl-N-benzhydrylamide (K-14585) on proteinase-activated receptor (PAR) 2-mediated intracellular signalling events. Experimental approach: Using NCTC2544 cells expressing PAR 2, we assessed the effects of K-14585 on PAR 2-mediated [ 3H] inositol phosphate accumulation, MAP kinase activation, p65 NFκB phosphorylation and DNA binding and IL-8 production. Key results: Pretreatment with K-14585 (5 μM) inhibited [ 3H] inositol phosphate levels stimulated by PAR 2- activating peptide Ser-Leu-Ile-Gly-Lys-Val (SLIGKV-OH) in PAR 2-expressing NCTC2544 cells. K-14585 pretreatment did not influence PAR 2-mediated extracellular regulated kinase activation but inhibited p38 MAP kinase phosphorylation. At a higher concentration (30 μM), K-14585 alone stimulated p38 MAP kinase activation. These effects were replicated in EAhy926 cells, endogenously expressing PAR 2, but not in parental or PAR 4-expressing NCTC2544 cells, suggesting these effects were PAR 2-dependent. SLIGKV-mediated stimulation of p38 MAP kinase phosphorylation was substantially reduced by the G q/11 inhibitor YM-254890, without affecting K-14585-mediated phosphorylation. Pretreatment with K-14585 inhibited PAR 2-mediated p65 NFκB phosphorylation and NFκB-DNA binding. K-14585 (30 μM) alone stimulated comparable NFκB reporter activity to SLIGKV-OH. K-14585 inhibited SLIGKV-stimulated IL-8 production, but given alone increased IL-8. While SLIGKV-induced IL-8 formation was reduced by both SB203580 and YM-254890, the response to K-14585 was sensitive to SB203580 but not YM-254890. Conclusions and implications: These data reveal that K-14585 has a duality of action functioning both as an antagonist and agonist due to either partial agonist actions or possible agonist-directed signalling. The data also suggest two modes of p38 MAP kinase activation emanating from PAR 2, one G q/11-dependent and the other G q/11-independent.",
keywords = "G signalling, Inositol phosphate, K-14585 peptide antagonist, P38 MAP kinase, PAR",
author = "Goh, {Fui Goon} and Ng, {Pei Yuen} and Mary Nilsson and Toru Kanke and Robin Plevin",
year = "2009",
month = "12",
doi = "10.1111/j.1476-5381.2009.00415.x",
language = "English",
volume = "158",
pages = "1695--1704",
journal = "British Journal of Pharmacology",
issn = "0007-1188",
publisher = "Wiley-Blackwell",
number = "7",

}

TY - JOUR

T1 - Dual effect of the novel peptide antagonist K-14585 on proteinase-activated receptor-2-mediated signaling

AU - Goh, Fui Goon

AU - Ng, Pei Yuen

AU - Nilsson, Mary

AU - Kanke, Toru

AU - Plevin, Robin

PY - 2009/12

Y1 - 2009/12

N2 - Background and purpose: Here we have examined the effects of the novel peptide antagonist N-[1-(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H- indol-5-yl]aminocarbonyl}-glycinyl-L-lysinyl-L-phenylalanyl-N-benzhydrylamide (K-14585) on proteinase-activated receptor (PAR) 2-mediated intracellular signalling events. Experimental approach: Using NCTC2544 cells expressing PAR 2, we assessed the effects of K-14585 on PAR 2-mediated [ 3H] inositol phosphate accumulation, MAP kinase activation, p65 NFκB phosphorylation and DNA binding and IL-8 production. Key results: Pretreatment with K-14585 (5 μM) inhibited [ 3H] inositol phosphate levels stimulated by PAR 2- activating peptide Ser-Leu-Ile-Gly-Lys-Val (SLIGKV-OH) in PAR 2-expressing NCTC2544 cells. K-14585 pretreatment did not influence PAR 2-mediated extracellular regulated kinase activation but inhibited p38 MAP kinase phosphorylation. At a higher concentration (30 μM), K-14585 alone stimulated p38 MAP kinase activation. These effects were replicated in EAhy926 cells, endogenously expressing PAR 2, but not in parental or PAR 4-expressing NCTC2544 cells, suggesting these effects were PAR 2-dependent. SLIGKV-mediated stimulation of p38 MAP kinase phosphorylation was substantially reduced by the G q/11 inhibitor YM-254890, without affecting K-14585-mediated phosphorylation. Pretreatment with K-14585 inhibited PAR 2-mediated p65 NFκB phosphorylation and NFκB-DNA binding. K-14585 (30 μM) alone stimulated comparable NFκB reporter activity to SLIGKV-OH. K-14585 inhibited SLIGKV-stimulated IL-8 production, but given alone increased IL-8. While SLIGKV-induced IL-8 formation was reduced by both SB203580 and YM-254890, the response to K-14585 was sensitive to SB203580 but not YM-254890. Conclusions and implications: These data reveal that K-14585 has a duality of action functioning both as an antagonist and agonist due to either partial agonist actions or possible agonist-directed signalling. The data also suggest two modes of p38 MAP kinase activation emanating from PAR 2, one G q/11-dependent and the other G q/11-independent.

AB - Background and purpose: Here we have examined the effects of the novel peptide antagonist N-[1-(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H- indol-5-yl]aminocarbonyl}-glycinyl-L-lysinyl-L-phenylalanyl-N-benzhydrylamide (K-14585) on proteinase-activated receptor (PAR) 2-mediated intracellular signalling events. Experimental approach: Using NCTC2544 cells expressing PAR 2, we assessed the effects of K-14585 on PAR 2-mediated [ 3H] inositol phosphate accumulation, MAP kinase activation, p65 NFκB phosphorylation and DNA binding and IL-8 production. Key results: Pretreatment with K-14585 (5 μM) inhibited [ 3H] inositol phosphate levels stimulated by PAR 2- activating peptide Ser-Leu-Ile-Gly-Lys-Val (SLIGKV-OH) in PAR 2-expressing NCTC2544 cells. K-14585 pretreatment did not influence PAR 2-mediated extracellular regulated kinase activation but inhibited p38 MAP kinase phosphorylation. At a higher concentration (30 μM), K-14585 alone stimulated p38 MAP kinase activation. These effects were replicated in EAhy926 cells, endogenously expressing PAR 2, but not in parental or PAR 4-expressing NCTC2544 cells, suggesting these effects were PAR 2-dependent. SLIGKV-mediated stimulation of p38 MAP kinase phosphorylation was substantially reduced by the G q/11 inhibitor YM-254890, without affecting K-14585-mediated phosphorylation. Pretreatment with K-14585 inhibited PAR 2-mediated p65 NFκB phosphorylation and NFκB-DNA binding. K-14585 (30 μM) alone stimulated comparable NFκB reporter activity to SLIGKV-OH. K-14585 inhibited SLIGKV-stimulated IL-8 production, but given alone increased IL-8. While SLIGKV-induced IL-8 formation was reduced by both SB203580 and YM-254890, the response to K-14585 was sensitive to SB203580 but not YM-254890. Conclusions and implications: These data reveal that K-14585 has a duality of action functioning both as an antagonist and agonist due to either partial agonist actions or possible agonist-directed signalling. The data also suggest two modes of p38 MAP kinase activation emanating from PAR 2, one G q/11-dependent and the other G q/11-independent.

KW - G signalling

KW - Inositol phosphate

KW - K-14585 peptide antagonist

KW - P38 MAP kinase

KW - PAR

UR - http://www.scopus.com/inward/record.url?scp=71249135633&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=71249135633&partnerID=8YFLogxK

U2 - 10.1111/j.1476-5381.2009.00415.x

DO - 10.1111/j.1476-5381.2009.00415.x

M3 - Article

VL - 158

SP - 1695

EP - 1704

JO - British Journal of Pharmacology

JF - British Journal of Pharmacology

SN - 0007-1188

IS - 7

ER -